Eli Lilly and Company (LLY) is a global leader in healthcare innovation, specializing in discovering, developing, and delivering life-changing medicines to address some of the world's most pressing ...

Eli Lilly and Company’s LLY shares declined 6.6% on Tuesday after the company lowered its sales guidance for full-year 2024 ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and ...

Earnings Report 5.284 USD Q4 2024 Earnings Release 02/06/2025 Earnings Report 4.894 USD Q1 2025 Earnings Release 05/01/2025 Earnings Report 5.682 USD Q2 2025 Earnings Release 08/07/2025 Earnings ...

The shares of pharmaceutical giant Eli Lilly (LLY) are falling 5% today after the company preannounced lower-than-expected fourth-quarter revenue. The firm estimated that it had generated Q4 sales of ...

JPMorgan analyst Chris Schott says Eli Lilly’s Q4 miss represents a buying opportunity as the company is positioned for strong growth in 2025. The company’s 2025 sales guidanc ...

David A. Ricks, Lilly’s CEO, attributed some of the shortfall to supply chain dynamics, noting that despite the setbacks, manufacturing capacity for incretin products is set to increase by at least 60 ...

BofA maintained LLY at Buy and a price target of $997.0, but said it was reviewing its estimates on the stock.

Eli Lilly and Company’s LLY shares declined 6.6% on Tuesday after the company lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers.